Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Gilead Sciences Inc.'s Truvada pill, used to treat people with HIV. (Paul Sakuma/AP)
Gilead Sciences Inc.'s Truvada pill, used to treat people with HIV. (Paul Sakuma/AP)

Gilead Sciences to acquire YM BioSciences for $510-million Add to ...

Shares in YM BioSciences Inc. surged more than 70 per cent after California-based Gilead Sciences Inc. announced an agreement to buy the Canadian company for about $510-million (U.S.).

Shares rose $1.17 to $2.83 on the Toronto Stock Exchange in Wednesday afternoon trading for the Mississauga-based drug development company.

More Related to this Story

The definitive agreement signed by the companies will see Gilead acquire YM for $2.95 per share in cash.

YM chief executive officer Nick Glover said Gilead Sciences has the research and development capabilities to more fully realize the potential of its lead drug, CYT387.

“This agreement represents a positive outcome both for myelofibrosis patients and for our shareholders,” Mr. Glover said in a news release.

The drug is used for myelofibrosis, a progressive, chronic bone marrow disorder.

“Gilead has the research and development capabilities and the resources needed to more fully realize the potential of CYT387 as a therapeutic advance for myelofibrosis patients and potentially for other indications.”

The transaction is expected to close in the first quarter of 2013.

 
Security Price Change
GILD-Q Gilead Sciences 68.17 1.38
2.066 %
Add to watchlist
  • GILD-Q
  • YM-T
Live Discussion of GILD on StockTwits
More Discussion on GILD-Q
Live Discussion of YM on StockTwits
More Discussion on YM-T

Topics:

In the know

Most popular video »

Highlights

More from The Globe and Mail

Most Popular Stories